Lobular carcinoma in situ of breast
ICD-10 D05.0 is a billable code used to indicate a diagnosis of lobular carcinoma in situ of breast.
Lobular carcinoma in situ (LCIS) of the breast is a non-invasive condition characterized by the abnormal proliferation of lobular cells within the breast lobules. Unlike invasive breast cancer, LCIS does not invade surrounding tissues but is considered a marker for increased risk of developing breast cancer in the future. Patients with LCIS typically present with no symptoms, and it is often discovered incidentally during breast biopsies performed for other reasons. The diagnosis is confirmed through histological examination, which reveals a proliferation of small, non-cohesive cells that fill and distend the lobules. While LCIS itself is not treated as a cancer, it necessitates careful surveillance due to the associated risk of progression to invasive breast cancer, which is estimated to be about 20-30% over the next 30 years. Management strategies often include regular clinical breast examinations, imaging studies such as mammography, and discussions regarding risk-reducing options, including chemoprevention or prophylactic mastectomy in high-risk patients.
Detailed pathology reports and treatment plans must be documented.
Patients diagnosed with LCIS during routine screening or biopsies.
Consideration of family history and genetic predispositions in risk assessment.
Imaging reports must clearly indicate findings related to LCIS.
Mammograms showing suspicious areas leading to biopsy.
Radiologists should document the rationale for imaging follow-up.
Used when a biopsy reveals LCIS and excision is performed for further evaluation.
Pathology report must confirm LCIS diagnosis.
Oncologists should ensure clear communication of findings to the patient.
No, lobular carcinoma in situ is not classified as breast cancer. It is a non-invasive condition that indicates an increased risk for developing breast cancer in the future.
